August 1, 2022 – Teleflex has been awarded a contract for the supply of Central Venous Access products from Vizient, Inc., the nation’s largest member-driven healthcare performance improvement company. The agreement is effective starting August 1, 2022.
Vizient provides solutions and services that improve the delivery of high-value care by aligning cost, quality, and market performance for more than 50% of the nation’s acute care providers. This includes 97% of the nation’s academic medical centers, and more than 20% of ambulatory care providers. Vizient provides expertise, analytics, and advisory services, as well as a contract portfolio that represents more than $130 billion in annual purchasing volume to improve patient outcomes and lower costs.
This new agreement allows Vizient members to take advantage of special pricing and terms pre-negotiated by Vizient for Central Venous Access products.
Teleflex, through its Arrow® Brand of CVC products, has been innovating for more than four decades to help healthcare providers optimize patient outcomes, minimize the risk of central line-associated infections (CLABSI), and efficiently streamline insertion procedures2-5.
The group purchasing agreement includes access to Teleflex Arrowg+ard Blue Plus® CVCs and Arrow® ErgoPack® Complete Systems.
Antimicrobial Arrowg+ard Blue Plus® CVCs are the only full-spectrum antimicrobial CVCs that protect against both gram-positive and gram-negative bacteria, fungi, and demonstrate a 67-100% reduction in CLABSI2-5.
Combined with antimicrobial Arrowg+ard Blue Plus® CVCs, Arrow® ErgoPack® Complete Systems help make it easy to:
- Standardize vascular access across a system
- Maintain a high standard of patient care
- Control costs and risks from infections6
Arrow® ErgoPack® Complete Systems help clinicians comply with third-party guideline recommendations7-10, including:
- CDC Category 1A &1B Recommendations
- SHEA Guidelines
- INS Standards of Practice
- OSHA Bloodborne Pathogens Standard